VEGFA and embryonal rhabdomyosarcoma: Although clinical trials of VEGF inhibitors in other types of cancers have exhibited mixed results [44]–[46], our data suggest that targeting the VEGF pathway may be a promising therapeutic option to curb tumor growth in a subset of high-risk ERMS patients.